NAV

RAPA-501-Allo

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
RAPA-501-Allo
DrugBank Accession Number
DB15890
Background

RAPA-501-ALLO is composed of T-cells extracted from healthy volunteers; these cells are then reprogrammed ex vivo in a process that involves de-differentiation and re-differentiation.1

Type
Biotech
Groups
Investigational
Biologic Classification
Cell transplant therapies
Other cell transplant therapies
Synonyms
Not Available
External IDs
  • RAPA-501-Allo

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

The hybrid TREG and Th2 phenotype of these cells inhibits the inflammatory pathways of COVID-19 through modulation of cytokines and chemokines and cross-regulation of Th1 and Th17 populations. This therapy also has been seen to mediate protection on lung alveolar tissue. The immunomodulation that occurs is in a T-cell receptor independent manner. Currently, RAPA-501-ALLO is being investigated against COVID-19.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. U.S. National Library of Medicine Clinical Trials: RAPA-501-Allo Off-the-Shelf Therapy of COVID-19 [Link]
Not Available

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2TerminatedTreatmentCoronavirus Disease 2019 (COVID‑19) / Severe COVID-19 Disease1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at September 30, 2020 16:31 / Updated at October 01, 2020 18:55